Alphamab Oncology
1.02
USD
-0.04
(-3.71%)
Important Dates
ALPHAMAB ONCOLOGY's next confirmed earnings release is scheduled for March 30, 2027.
| Earnings Date | 3/30/2027 |
Share Statistics
As of December 31, 2025, ALPHAMAB ONCOLOGY has 968.57M shares outstanding.
| Shares Outstanding | 968.57M |
Financial Position
As of December 31, 2025, ALPHAMAB ONCOLOGY maintains a current ratio of 5.67, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.67 |
| Quick Ratio | 4.81 |
| Debt / Equity | 7.19 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2025.
| Employee Count | 459.00 |
Balance Sheet
USDAs of December 31, 2025, ALPHAMAB ONCOLOGY holds 193.11M in cash and equivalents against 17.59M in total debt, resulting in a net debt position of -20.04M. Total book value stands at 244.67M, with working capital of 187.76M providing operational flexibility.
| Cash & Cash Equivalents | 193.11M |
| Total Debt | 17.59M |
| Net Debt | -20.04M |
| Equity (Book Value) | 244.67M |
| Book Value Per Share | 0.25 |
| Working Capital | 187.76M |